Werewolf Therapeutics price target lowered to $4 from $10 at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $4 from $10 and keeps a Buy rating on the shares after the company announced a pipeline and business update. While the shares traded down on the news, the update “underscores tangible progress” toward Werewolf’s primary value driver, the “creation of safer, systemically deliverable therapies,” the analyst tells investors in a research note.